Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Contrarian Investing -- Ignore unavailable to you. Want to Upgrade?

To: pcyhuang who wrote (687)	11/6/2006 7:26:36 PM
From: pcyhuang	Read Replies (1) \| Respond to of 4080

NBIX -- Focus on Value Its funny how sometimes the baby gets thrown out with the bathwater. Its regretable that the main focus has been on Indiplon while giving absolutly no value to pipeline of other candidates. Preliminary top line results from a second Phase II 3-month clinical trial in endometriosis evaluating additional dose response expected in the 4th Quarter of 2006. Results from a Phase II dose response trial involving patients with stable congestive heart failure (CHF) expected in the 4th Quarter 2006. Neurocrine expects the first exploratory studies in patients with irritable bowel syndrome (IBS) to start during the 4th Quarter of 2006. Given the fact that NBIX is currently trading at CASH VALUE, there is no way that this value goes missed for long on wall street. Full Story: messages.finance.yahoo.com

To: pcyhuang who wrote (687)	11/6/2006 10:31:31 PM
From: pcyhuang	Respond to of 4080

NBIX -- Advancing Six New Drugs Neurocrine is advancing six drug candidates through clinical development. The Company is expecting to report on several Phase II clinical trials in the fourth quarter of 2006 and throughout 2007. At the same time, Neurocrine scientists will continue to build Neurocrine's pipeline and meet the Company-wide goal of bringing one new compound into development each year. GnRH Antagonists for endometriosis: * Initiated a 6-month Phase IIb clinical trial with NBI-56418 for the treatment of endometriosis during the 4th Quarter 2006. * Preliminary top line results from a second Phase II 3-month clinical trial in endometriosis evaluating additional dose response expected in the 4th Quarter of 2006. Urocortin 2 for CHF: * Results from a Phase II dose response trial involving patients with stable congestive heart failure (CHF) expected in the 4th Quarter 2006. CRF Antagonists for IBS and Anxiety/Depression: * Neurocrine expects the first exploratory studies in patients with irritable bowel syndrome (IBS) to start during the 4th Quarter of 2006. * Neurocrine expects Phase II "proof of concept" trials in two indications, IBS and anxiety, to be initiated late in 2006. * A back up compound is currently in Phase I multi-dose trials. Selective Norepinephrine Reuptake Inhibitor (sNRI) for Neuropathic Pain * New clinical candidate for neuropathic pain expected to enter Phase I clinical trials in late 4th Quarter 2006 or early 1st Quarter 2007. pcyhuang